Target volume delineation of the neck for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas
- PMID: 40907527
- DOI: 10.1016/S1470-2045(25)00327-4
Target volume delineation of the neck for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas
Abstract
The Chinese Society for Therapeutic Radiology Oncology, the Chinese Anti-Cancer Association, the Chinese Society of Clinical Oncology, the Head and Neck Cancer International Group, the European Society for Radiotherapy and Oncology, and the American Society for Radiation Oncology collaboratively developed evidence-based guidelines and a comprehensive contouring atlas for neck target volume delineation in nasopharyngeal carcinoma. These guidelines address five key challenges in modern radiotherapy practice: margin design of clinical target volume; nodal target volume delineation after induction chemotherapy; delineation of equivocal nodes evident on imaging; low-risk clinical target volume delineation based on regional stepwise extension patterns; and modifications for anatomical boundaries of lymphatic areas. Developed through a rigorous systematic review and expert appraisal process by a panel of 50 international, multidisciplinary members from 17 countries and regions, these guidelines incorporate the latest advances in nasopharyngeal carcinoma diagnosis and treatment. They reflect contemporary therapeutic concepts and elaborate on current practice variations. These guidelines aim to standardise global practice, substantially improving consistency and reducing variability in nasopharyngeal carcinoma radiotherapy target delineation.
Copyright © 2025 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.
Conflict of interest statement
Declaration of interests TK receives Health Science Research Grants for the Grant-in-Aid for Cancer Research (Ministry of Health, Labour and Welfare of Japan), and National Cancer for Research and Development Funds (Japan); speakers bureau fees from Merck Biopharma, Hitachi, Merck & Co, Janssen Pharmaceutical, AstraZeneca, Otsuka Pharmaceutical Factory, Shizuoka Cancer Center, Tohoku University, and Sapporo Medical University; and writing fees from Nankodo, Tokyo Igakusha, Gakken Holdings, Nagoya University Press, Gan to Kagakuryoho Publishing, Gakken Medical Shujunsha, and Convention Linkage. SSY discloses research grants from Merck, EMD Serono, Bristol-Myers Squibb, and Nanobiotix; royalties from UpToDate and Springer; and honoraria from the American Society for Radiation Oncology and Elsevier. NL has received honoraria from Shanghai JoAnn Medical Technology, Lizhi Network Technology, Yingming Consulting, and Varian; serves on advisory boards for Galera, GSK, LEO Pharma, Merck, Merck Serono, and Nanobiotix; and holds stock in LEO Pharma. MLKC declares research grants from Bayer, Beigene, Decipher Biosciences, and ImmunoSCAPE; holds a patent for High Sensitivity Lateral Flow Immunoassay For Detection of Analyte in Sample (10202107837T, Singapore); serves on advisory boards for AstraZeneca, Janssen, Merck & Co, Seagen, and the Varian Thought Leadership Council; holds board positions as Director of Digital Life Line and Trustee of Alice's Arc Charity for Pediatric RMS; owns stock ownership in Digital Life Line; and has received other financial support from AstraZeneca, Decipher Bioscience, and Varian. JF acknowledges research grants from Siemens-Varian and serves as a board member of the European Head and Neck Society. HL reports research grants from Ion Beam Applications, the EU, and the Dutch Cancer Society; consulting fees from Ion Beam Applications; serves as Chair of the Safety Monitoring Committee for the UPGRADE trial, and on advisory boards for Ion Beam Applications and RaySearch; and has institutional collaborative research contracts with financial support from Ion Beam Applications, RaySearch, Elekta, Mirada, and Siemens. FS discloses research grants from Siemens-Varian; honoraria and travel support from Varian Medical System, the American College of Radiology, and Castle Biosciences; participation on the Varian Noona Medical Advisory Board; and leadership roles as chair of the Henry Ford Medical Group Board of Governors and Vice-Chair of the Department of Radiation Oncology. HL declares research grants from Ion Beam Applications, the EU, and the Dutch Cancer Society; consulting fees from Ion Beam Applications; advisory role for University Medical Center Nijmegen, Ion Beam Applications, and RaySearch; and institutional collaborative research contracts with financial support from Ion Beam Applications, RaySearch, Elekta, Mirada, and Siemens. All other authors declare no competing interests.
Similar articles
-
Primary target volume delineation for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas.Lancet Oncol. 2025 Sep;26(9):e477-e487. doi: 10.1016/S1470-2045(25)00326-2. Lancet Oncol. 2025. PMID: 40907526
-
International Consensus Guideline on Delineation of the Clinical Target Volumes at Different Dose Levels for Nasopharyngeal Carcinoma (2024 Version).Int J Radiat Oncol Biol Phys. 2025 Oct 1;123(2):415-431. doi: 10.1016/j.ijrobp.2025.05.019. Epub 2025 May 24. Int J Radiat Oncol Biol Phys. 2025. PMID: 40419028
-
International Consensus Guidelines on the Delineation of Radiation Therapy Target Volumes for Nasopharyngeal Carcinoma After Induction Chemotherapy Using a 2-Round Modified Delphi Survey.Pract Radiat Oncol. 2025 Jul-Aug;15(4):347-366. doi: 10.1016/j.prro.2025.01.015. Epub 2025 Mar 26. Pract Radiat Oncol. 2025. PMID: 40146085
-
A novel multimodal adaptive delineation model for primary tumors and lymph node metastases in multi-center nasopharyngeal carcinoma radiotherapy.Comput Methods Programs Biomed. 2025 Oct;270:108965. doi: 10.1016/j.cmpb.2025.108965. Epub 2025 Jul 12. Comput Methods Programs Biomed. 2025. PMID: 40682906
-
Improving performance in radiation oncology: An international systematic review of quality improvement interventions.Radiother Oncol. 2025 May;206:110798. doi: 10.1016/j.radonc.2025.110798. Epub 2025 Feb 20. Radiother Oncol. 2025. PMID: 39986541
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources